iShares MSCI Poland UCITS ETF USD (Acc) (IBCJd)

Overview

MorphoSys AG is a biopharmaceutical company that excels in the development and commercialization of innovative therapeutics for patients across the globe dealing with various cancers and autoimmune diseases. With its subsidiaries, MorphoSys extends its reach within Europe, Asia, and the United States, pushing the boundaries of medical biotechnology since its foundation in 1992. Based in Planegg, Germany, the company is at the forefront of bringing groundbreaking treatment options from the laboratory to the clinic, backed by strategic collaboration and licensing agreements with leading entities like I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Incyte Corporation, and Xencor, Inc.

Products and Services

• Pelabresib

  - Currently in Phase 3 trials targeting the treatment of myelofibrosis and essential thrombocythemia, focusing on improving the quality of life for patients suffering from these conditions.

• Tulmimetostat

  - A versatile product candidate undergoing Phase 1/2 trials aimed at combating solid tumors and lymphomas, illustrating the company's commitment to expanding the range of treatable cancers.

• Felzartamab

  - An antibody specifically directed against CD38 to tackle renal autoimmune diseases as well as relapsed/refractory multiple myeloma, seeking to advance treatment effectiveness and patient outcomes.

• Ianalumab

  - This promising candidate is in Phase 3 clinical trials for addressing autoimmune diseases such as Sjögren's disease and lupus nephritis, potentially offering new hope for patients with these conditions.

• Abelacimab

  - In Phase 3 trials, Abelacimab is being developed for the prevention of venous thromboembolism and the treatment of cancer-associated thrombosis, reflecting MorphoSys' efforts in combating complications related to cancer.

• Setrusumab

  - Aimed at individuals with osteogenesis imperfecta, Setrusumab is progressing through Phase 2/3 trials to potentially offer a novel treatment option for this genetic disorder affecting bones.

• Bimagrumab

  - With a current status of Phase 2b trials, Bimagrumab targets adult obesity, a prevalent global health issue, indicating MorphoSys' dedication to addressing widespread health challenges.

• MOR210/TJ210/HIB210

  - This investigational drug is in Phase 1 clinical trials for the treatment of relapsed or refractory advanced solid tumors, showcasing the company's innovative approach towards cancer therapy.

• NOV-8

  - Undergoing Phase 2 trials, NOV-8 is a candidate for tackling pulmonary sarcoidosis and dermatitis, diseases that significantly impact patients’ quality of life.